Dr. Scott Plevy became Chief Scientific Officer of Synlogic Therapeutics in May 2019. He is a gastroenterologist and molecular immunologist who most recently served as Vice President, Gastroenterology Disease Area Leader and IL-23 Pathway Leader at Janssen Research & Development, LLC, after a successful career in academia. He has published over 100 refereed papers, served as the lead investigator on multiple early-phase clinical trials and performed translational research to advance the understanding of novel immunologic interventions in inflammatory bowel disease. Dr. Plevy earned both an M.D. degree and an A.B. in mathematics from Columbia University and completed residency training in internal medicine at Brigham and Women’s Hospital in Boston. He subsequently completed a clinical fellowship in gastroenterology at the University of California at Los Angeles (UCLA), and a postdoctoral research fellowship at the Howard Hughes Medical Institute, Department of Microbiology and Immunology, UCLA School of Medicine.
The human microbiome has been proposed to form an integral part of human health and its role in disease is a part of large investigations. Furthermore, the microbiome is under evaluation as both a source of therapeutics as well as diagnostics. The current state of the science and medicine in relation to precision medicine approaches will be discussed.